The other problem with creams/gels is the transferance from the person who requires the treatment, to a partner on contact, therefore limiting the impact of the dose to the relevant party.
That has been seen as a major advantage with the delivery system developed by Acrux.
I am personally happy with Vivus pulling out and therefore Axiron being back in the hands of Acrux. I wouldn't be surprised if Eli Lilly step in and look after the marketing of this also, however time will tell.
Good luck to all holders, and any prospective investors. DYOR
Add to My Watchlist
What is My Watchlist?
